The Role of Antidiabetic Therapies in Mild Cognitive Impairment and Alzheimer's Disease: A Systematic Review of Metformin, Pioglitazone, and GLP-1 Receptor Agonists
Metformin may help preserve memory in early Alzheimer's disease within specific metabolic subgroups, hinting that diabetes drugs deserve larger, targeted trials in cognition.
This systematic review of 11 studies evaluating antidiabetic therapies in Alzheimer's disease and MCI finds metformin showing selective cognitive benefits (episodic memory) in early-stage disease and specific metabolic subgroups, while evidence for GLP-1 RA and pioglitazone neuroprotective efficacy remains insufficient due to small and heterogeneous trials. The finding suggests metabolic pathway targeting in AD may have meaningful signal but requires larger purpose-designed trials.
What the study was
- Study design
- Systematic review of RCTs and observational studies
- Population
- Patients with Alzheimer's disease or mild cognitive impairment
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- International Journal of Molecular Sciences
Why it surfaced
Systematic review addressing GLP-1 in cognitive decline — relevant to aging/longevity + cardiometabolic watchlist intersection. Abstract was truncated; author list not fully retrieved.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.